Loading institutional data...
Loading institutional data...
Held by 320 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
2/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$22M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -29%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 11-yr range · 96th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 11-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.0× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 13.8 | 16.3 | 40.8 | 22.7 | 24.4 | 24.0 | 24.5 | 22.0 |
| Gross Profit | 86.2 | 83.7 | 59.2 | 77.3 | 75.6 | 76.0 | 75.5 | 55.7 |
| R&D | 27.4 | — | — | — | — | — | — | — |
| SG&A | 65.9 | 74.5 | 76.2 | 61.0 | 68.2 | 71.2 | 68.1 | 65.4 |
| Operating Income | -7.2 | -21.2 | -54.9 | -11.2 | -29.1 | -40.9 | -31.9 | -39.3 |
| Income Tax | 0.3 | -27.6 | -5.3 | 0.1 | 0.3 | 0.3 | 0.2 | -1.1 |
| Net Income | -7.1 | 6.5 | -53.5 | -16.9 | -35.1 | -42.8 | -38.2 | -37.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on GKOS: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $507.4M 100.0% | $383.5M 100.0% | $314.7M 100.0% | $282.9M 100.0% | $294.0M 100.0% | $225.0M 100.0% | $237.0M 100.0% | $181.3M 100.0% | $159.3M 100.0% | $114.4M 100.0% |
| Cost of Revenue | $111.8M 22.0% | $94.0M 24.5% | $75.6M 24.0% | $69.0M 24.4% | $66.6M 22.7% | $91.7M 40.8% | $38.6M 16.3% | $25.1M 13.8% | $21.1M 13.2% | $16.2M 14.1% |
| Cost of Products | — | — | — | — | — | — | — | — | $21.1M 13.2% | $16.2M 14.1% |
| Gross Profit | $282.8M 55.7% | $289.5M 75.5% | $239.1M 76.0% | $213.9M 75.6% | $227.4M 77.3% | $133.2M 59.2% | $198.4M 83.7% | $156.2M 86.2% | $138.2M 86.8% | $98.2M 85.9% |
| Research & Development | — | — | — | — | — | — | — | $49.7M 27.4% | $38.9M 24.4% | $29.2M 25.5% |
| Selling, General & Admin | $331.7M 65.4% | $261.2M 68.1% | $224.1M 71.2% | $192.9M 68.2% | $179.3M 61.0% | $171.4M 76.2% | $176.6M 74.5% | $119.5M 65.9% | $96.3M 60.4% | $64.8M 56.6% |
| Total Operating Expenses | $482.4M 95.1% | $411.8M 107.4% | $367.8M 116.9% | $296.2M 104.7% | $260.3M 88.5% | $256.8M 114.2% | $248.7M 104.9% | $169.2M 93.3% | $140.5M 88.2% | $94.0M 82.2% |
| Operating Income | -$199.6M -39.3% | -$122.4M -31.9% | -$128.7M -40.9% | -$82.3M -29.1% | -$32.9M -11.2% | -$123.6M -54.9% | -$50.3M -21.2% | -$13.0M -7.2% | -$2.3M -1.4% | $4.2M 3.7% |
| Interest Expense | $4.6M 0.9% | $10.0M 2.6% | $13.6M 4.3% | $13.7M 4.9% | $13.4M 4.5% | $14.1M 6.3% | $2.6M 1.1% | — | — | — |
| Other Income (Expense), net | $6.6M 1.3% | -$23.2M -6.1% | -$5.0M -1.6% | -$16.1M -5.7% | -$16.4M -5.6% | -$8.8M -3.9% | $256K 0.1% | $634K 0.3% | $2.3M 1.4% | $324K 0.3% |
| Pretax Income | -$193.0M -38.0% | -$145.6M -38.0% | -$133.7M -42.5% | -$98.4M -34.8% | -$49.3M -16.8% | -$132.3M -58.8% | -$50.0M -21.1% | -$12.4M -6.8% | $1K 0.0% | $4.6M 4.0% |
| Income Tax Expense | -$5.4M -1.1% | $771K 0.2% | $934K 0.3% | $766K 0.3% | $326K 0.1% | -$12.0M -5.3% | -$65.5M -27.6% | $583K 0.3% | $93K 0.1% | $43K 0.0% |
| Net Income | -$187.7M -37.0% | -$146.4M -38.2% | -$134.7M -42.8% | -$99.2M -35.1% | -$49.6M -16.9% | -$120.3M -53.5% | $15.4M 6.5% | -$13.0M -7.1% | -$92K -0.1% | $4.5M 4.0% |
| Per Share | ||||||||||
| EPS (Basic) | $-3.28 | $-2.77 | $-2.78 | $-2.09 | $-1.07 | $-2.70 | $0.41 | $-0.37 | $0.00 | $0.14 |
| EPS (Diluted) | $-3.28 | $-2.77 | $-2.78 | $-2.09 | $-1.07 | $-2.70 | $0.37 | $-0.37 | $0.00 | $0.12 |
| Weighted Avg Shares (Basic) | 57.2M | 52.8M | 48.4M | 47.4M | 46.4M | 44.5M | 37.4M | 35.3M | 34.4M | 32.9M |
| Weighted Avg Shares (Diluted) | 57.2M | 52.8M | 48.4M | 47.4M | 46.4M | 44.5M | 41.1M | 35.3M | 34.4M | 36.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| GKOS | $9.4B | — | — | 18.5× | 32.3% | 55.7% | -37.0% | -28.6% | -28.6% | — | 320 |
Peers = companies sharing GKOS's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.